Metastatic Breast Cancer: Treatment Approaches And Options

Targeted Treatment Advances for Metastatic Breast Cancer

Targeted therapies aim to interfere with molecules or processes that contribute to the growth and spread of cancer cells. In the United States, these treatments are selected based on specific tumor biomarkers, such as HER2 overexpression or mutations in genes like BRCA1 and BRCA2. Targeted therapies can be administered alone or in combination with other modalities, depending on individual patient and disease factors.

For patients whose cancer overexpresses the HER2 protein, agents such as trastuzumab or pertuzumab have become integral to standard care. These medications may be administered intravenously and are often included in combination regimens. The accessibility and insurance coverage for targeted HER2 therapies can influence their use and may impact treatment planning discussions in the United States.

In hormone receptor–positive breast cancer, inhibitors of the cyclin-dependent kinase (CDK) pathway, such as palbociclib, ribociclib, or abemaciclib, have become widely considered. These oral agents function by disrupting cellular processes involved in cancer cell division. Side effects and drug interactions are closely monitored, and ongoing studies aim to refine their optimal use in metastatic settings.

PARP inhibitors are another class of targeted treatment particularly relevant to patients with germline BRCA-related mutations. Agents such as olaparib or talazoparib may be incorporated for individuals who have progressed on prior lines of therapy. In the United States, genetic testing is increasingly employed to identify candidates who may benefit from PARP inhibitors, aligning with a broader move toward precision medicine.